In summary, whereas S1PR3 activation on tumor cells would most likely worsen cancer prognosis, an immune cell specific S1PR3 agonist might serve as a potential pharmacological drug to enhance anti-tumor immune response. Here, S1PR3 is linked to neoplasm.